Safety of Bisphosphonates in the Treatment of Osteoporosis

Robert R. Recker; E. Michael Lewiecki; Paul D. Miller; James Reiffel

doi:10.1016/j.amjmed.2008.12.004

Safety of Bisphosphonates in the Treatment of Osteoporosis

Robert R. Recker, E. Michael Lewiecki, Paul D. Miller, James Reiffel

Department of Medicine

Research output: Contribution to journal › Article

75 Scopus citations

Abstract

In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

Original language	English (US)
Pages (from-to)	S22-S32
Journal	American Journal of Medicine
Volume	122
Issue number	2 SUPPL.
DOIs	https://doi.org/10.1016/j.amjmed.2008.12.004
State	Published - Feb 3 2009

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1016/j.amjmed.2008.12.004

Fingerprint Dive into the research topics of 'Safety of Bisphosphonates in the Treatment of Osteoporosis'. Together they form a unique fingerprint.

Cite this

Recker, R. R., Lewiecki, E. M., Miller, P. D., & Reiffel, J. (2009). Safety of Bisphosphonates in the Treatment of Osteoporosis. American Journal of Medicine, 122(2 SUPPL.), S22-S32. https://doi.org/10.1016/j.amjmed.2008.12.004

@article{90b7b9e4a0a44d47bd5f8061df4efc68,

title = "Safety of Bisphosphonates in the Treatment of Osteoporosis",

abstract = "In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).",

author = "Recker, {Robert R.} and Lewiecki, {E. Michael} and Miller, {Paul D.} and James Reiffel",

year = "2009",

month = feb,

day = "3",

doi = "10.1016/j.amjmed.2008.12.004",

language = "English (US)",

volume = "122",

pages = "S22--S32",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "2 SUPPL.",

}

TY - JOUR

T1 - Safety of Bisphosphonates in the Treatment of Osteoporosis

AU - Recker, Robert R.

AU - Lewiecki, E. Michael

AU - Miller, Paul D.

AU - Reiffel, James

PY - 2009/2/3

Y1 - 2009/2/3

N2 - In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

AB - In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

UR - http://www.scopus.com/inward/record.url?scp=58949086108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949086108&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2008.12.004

DO - 10.1016/j.amjmed.2008.12.004

M3 - Article

C2 - 19187809

AN - SCOPUS:58949086108

VL - 122

SP - S22-S32

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2 SUPPL.

ER -